Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Shankari Nair
Observed name:
Nair, Shankari
Institution:
Bayer (Germany)
Observed institutions:
University of Cape Town,
South African Nuclear Energy Corporation (South Africa),
iThemba Laboratory,
Bayer (Germany),
National Research Foundation
ORCID:
0000-0003-2221-1987
Observed ORCID:
0000-0003-2221-1987
OpenAlex ID:
A5060782907
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
2021
·
Julie Bolcaen
, Janke Kleynhans
, et al.
·
Theranostics
·
70
PDF
The Impact of Dose Rate on DNA Double-Strand Break Formation and Repair in Human Lymphocytes Exposed to Fast Neutron Irradiation
2019
·
Shankari Nair
, Monique Engelbrecht
, et al.
·
International Journal of Molecular Sciences
·
31
PDF
Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
·
Clinical Cancer Research
·
27
PDF
Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma
2021
·
Julie Bolcaen
, Shankari Nair
, et al.
·
Pharmaceuticals
·
24
PDF
Estimating the Relative Biological Effectiveness of Auger Electron Emitter 123I in Human Lymphocytes
2020
·
Hein Fourie
, Shankari Nair
, et al.
·
Frontiers in Physics
·
17
PDF
Synthesis and evaluation of benzoylbenzofurans and isoflavone derivatives as sirtuin 1 inhibitors with antiproliferative effects on cancer cells
2022
·
Mamoalosi A. Selepe
, Phaladi Kunyane
, et al.
·
Bioorganic Chemistry
·
16
PDF
DNA damage response of haematopoietic stem and progenitor cells to high-LET neutron irradiation
2021
·
Monique Engelbrecht
, Roya Ndimba
, et al.
·
Scientific Reports
·
14
PDF
Perspective on the Use of DNA Repair Inhibitors as a Tool for Imaging and Radionuclide Therapy of Glioblastoma
2022
·
Liesbeth Everix
, Shankari Nair
, et al.
·
Cancers
·
8
PDF
An Automated Microscopic Scoring Method for the γ-H2AX Foci Assay in Human Peripheral Blood Lymphocytes
2021
·
Shankari Nair
, Samantha Cairncross
, et al.
·
Journal of Visualized Experiments
·
8
PDF
Immunological Changes During Space Travel: A Ground-Based Evaluation of the Impact of Neutron Dose Rate on Plasma Cytokine Levels in Human Whole Blood Cultures
2020
·
Randall Fisher
, Bjorn Baselet
, et al.
·
Frontiers in Physics
·
6
PDF
Mechanistic Sequence of Histone Deacetylase Inhibitors and Radiation Treatment: An Overview
2024
·
Elsie Neo Seane
, Shankari Nair
, et al.
·
Pharmaceuticals
·
4
Multi-Target Inhibitor CUDC-101 Impairs DNA Damage Repair and Enhances Radiation Response in Triple-Negative Breast Cell Line
2024
·
Elsie Seane
, Shankari Nair
, et al.
·
Pharmaceuticals
·
3
Exploring Hypofractionated Radiotherapy Efficacy in Prostate Cancer: In Vitro Insights
2024
·
Peter du Plessis
, Pauline Busisiwe Nkosi
, et al.
·
Radiation
·
2
PDF
Auxiliary-controlled diastereoselective synthesis of a syn C-6-epimer of the ADAM 10 inhibitor GI254023X
2020
·
Shankari Nair
, Jan Rijn Zeevaart
, et al.
·
ARKIVOC
·
2
PDF
In Vitro Perspective on Hypofractionated Radiotherapy in Breast Cancer
2026
·
Peter du Plessis
, Pauline Busisiwe Nkosi
, et al.
·
Radiation
·
1
PDF
A Validation Study on Immunophenotypic Differences in T-lymphocyte Chromosomal Radiosensitivity between Newborns and Adults in South Africa
2021
·
Monique Engelbrecht
, Roya Ndimba
, et al.
·
Radiation
·
1
PDF
Abstract 7202: Comparative evaluation of 225Ac-PSMA-Trillium with other 225Ac-PSMA-SMOL assets in a preclinical prostate cancer xenograft model
2026
·
Urs B. Hagemann
, Maria Spelling
, et al.
·
Cancer Research
Cudc-101 and Proton Irradiation Reduces Migration and Invasion Capacity of Triple Negative Breast Cell Line
2024
·
Elsie Seane
, Shankari Nair
, et al.
·
Preprints.org
PDF
Supplementary Table S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
Supplementary Figure S3 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
PDF
Supplementary Figure S7 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
Supplementary Figure S6 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
Supplementary Methods S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
Supplementary Figure S5 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
PDF
Supplementary Figure S4 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
2024
·
Christoph A. Schatz
, Sabine Zitzmann-Kolbe
, et al.
Show more works
View as search
Works count:
36
Citation count:
234
H-index:
8
I10-index:
7
Year
Topic
Type